Steffen Sammet to Receptors, Vascular Endothelial Growth Factor
This is a "connection" page, showing publications Steffen Sammet has written about Receptors, Vascular Endothelial Growth Factor.
Connection Strength
0.022
-
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010 May 10; 28(14):2323-30.
Score: 0.022
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.